Vol. 119 No. 1 (2014)
Original Article

Targeting RANKL in the management of bone loss in patient with breast cancer

PDF
  • Vanessa Nicolin,
  • Roberto Valentini

Published 2014-06-27

Keywords

  • receptor activator of nuclear factor-κB ligand,
  • osteoclast differentiation factor,
  • osteoprotegerin ligand (OPG-l),
  • breast cancer,
  • TNF,
  • tumour necrosis factor,
  • TNF receptor
    • ...More
    Less

How to Cite

Nicolin, V., & Valentini, R. (2014). Targeting RANKL in the management of bone loss in patient with breast cancer. Italian Journal of Anatomy and Embryology, 119(1), 44–48. Retrieved from https://oajournals.fupress.net/index.php/ijae/article/view/1213
Copyright Notice

Abstract

The receptor activator of nuclear factor-κB ligand (RANKL), its signaling receptor RANK, and its natural decoy receptor OPG are members of the tumour necrosis factor (TNF) and TNF receptor superfamily and are best known for their essential role in controlling osteoclastogenesis. RANKL in bone has also been shown to serve as a chemoattractant for cancer cells, thus explaining the tropism of certain cancers such as breast and prostate cancer to preferentially metastasize to bone. Here, we will discuss the important role of RANKL and its possible role in the management of bone loss in patients with breast cancer.

PDF

Most read articles by the same author(s)

1 2 > >>